KRAKÓW, Poland, May 7, 2024
/PRNewswire/ -- Selvita S.A. [WSE: SLV] announced today completion
of a strategic transaction in which it has acquired 100% of shares
in PozLab. The closing of the transaction comes shortly after the
announcement of the transaction on March 27,
2024.
PozLab is a contract development and manufacturing organization
("CDMO") offering expert drug product development services and
small pilot plant capabilities, including analytical, formulation,
and process development competencies, followed by microbiological
testing. Moreover, PozLab holds a GMP license for the manufacture
of medical and investigational products. The Company currently
employs over 80 dedicated subject matter experts and is located in
state-of-the-art R&D facilities in Poznan, Poland, which offer approx. 1700 m2 of research space.
The acquisition of PozLab substantially expands Selvita's
capabilities in the rapidly growing pharmaceutical research sector.
Selvita extends its value chain beyond preclinical research,
enabling, in particular, the provision of small molecule drug
manufacturing services for early-stage clinical trials. This
strategic move enriches Selvita's portfolio with additional
valuable competencies, positioning the company as a comprehensive
solution provider in the pharmaceutical industry.
We are very excited that as of today, PozLab is formally part
of the Selvita Group. A lot of effort has gone into the completion
of this transaction, and we are certain that it's a very important
milestone for the development of Selvita's CDMO offer.
I would like to extend a very warm welcome to our new
colleagues in Poznan. It's wonderful to have them on board and I am
looking forward to all the synergies this new relationship will
bring - said Bogusław Sieczkowski, President of the Management
Board of Selvita.
About Selvita
(SLV)
Selvita is one of the leading preclinical contract research
organizations in Europe, driven by
a clear mission: to offer a comprehensive scope of services
bridging the gap between early drug discovery and the clinical
stage of drug development.
Selvita provides comprehensive solutions supporting Clients and
their drug discovery projects, across a broad range of therapeutic
areas, specializing in infectious diseases, inflammation, fibrosis,
and oncology. The Company offers a range of stand-alone or fully
integrated drug discovery and development solutions spanning the
entire value chain from early drug discovery to preclinical
development both for small molecules and therapeutic antibodies. On
top of that Selvita offers drug product development and contract
testing studies.
Selvita, established in 2007, operates globally with over 900
highly qualified employees, of which over 40% hold a PhD degree.
The Company's research sites are in Krakow (HQ), Poznan and Wroclaw
Poland, and Zagreb, Croatia. The
international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well
as in Cambridge, UK.
Ardigen, a bioinformatics company harnessing advanced Artificial
Intelligence methods for novel precision medicine, is part of
Selvita Group portfolio of companies. The company employs over 150
professionals.
Selvita is listed on the Warsaw Stock Exchange (WSE: SLV). For
more information, please see www.selvita.com.
View original
content:https://www.prnewswire.com/news-releases/selvita-completes-acquisition-of-pozlab-and-significantly-expands-its-drug-development-capabilities-302137850.html
SOURCE Selvita S.A.